ImmunoBrain Checkpoint News
3 articles
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Francis S. Collins to its board of directors. Dr. Collins, a renowned physician-scientist and former director of the National Institutes of Health, brings extensive experience in biomedical research. His appointment is expected to bolster ImmunoBrains efforts in developing novel immunotherapies for neurodegenerative diseases, particularly Alzheimers. The company is currently conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, which targets an inhibitory immune checkpoint pathway. Supported by grants from the National Institute on Aging and the Alzheimers Association, the trial is showing encouraging interim results, with topline data expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...
ImmunoBrain Checkpoint Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Rochelle Walensky to its board of directors. The company is conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, aimed at treating Alzheimers disease and other forms of dementia. Dr. Walensky, with a background in infectious diseases and public health, brings valuable expertise to the company. The appointment is seen as a positive step in advancing ImmunoBrains mission to develop innovative therapies for neurodegenerative diseases. The company is supported by grants from the National Institute on Aging and the Alzheimers Association, with topline data from the trial expected in Q1 2026.
Management ChangesProduct Stage
growth-positive
Lundbeck Obtains Rights to Research that Targets Immune Checkpoint...
Lundbeck has obtained the rights to IBCs research on treatment for Alzheimers disease, specifically targeting immune checkpoint pathways. The research focuses on blocking the PD-1/PD-L1 pathway, which has shown promise in cancer treatment and could potentially be extended to neurodegenerative diseases. Lundbeck will provide funding for additional research and has the option to take over the rights and activities relating to this technology in the future. The partnership with IBC is part of Lundbecks strategy to supplement its own research activities.
Partners
